{"id":2995,"date":"2016-12-23T12:56:42","date_gmt":"2016-12-23T11:56:42","guid":{"rendered":"https:\/\/www.farmaindustria.es\/web_en\/?p=2995"},"modified":"2016-12-23T12:57:19","modified_gmt":"2016-12-23T11:57:19","slug":"ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients","status":"publish","type":"post","link":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/","title":{"rendered":"The II Somos Pacientes (\u2018We Are Patients\u2019) Awards recognized the best initiatives developed for the benefit of patients"},"content":{"rendered":"<p style=\"text-align: justify\">Cancer, leukodystrophies, rare pediatric diseases, epilepsy, multiple sclerosis and diabetes. \u00a0The presentation of the II Somos Pacientes Awards on Tuesday December 13th, saw different initiatives being developed and given recognition specifically within the area of the aforementioned six diseases.\u00a0 The Awards recognize the effort, dedication, talent and imagination that patients\u2019 associations have carried out throughout the year, in order to offer assistance, services and solutions to their associates and society in general.<\/p>\n<p style=\"text-align: justify\">The \u2018We Are Patients\u2019 Awards are organised by the Farmaindustria Foundation through the online community of patients and patients with disabilities, \u2018We Are Patients\u2019. The finalists and winners in this particular edition are just one example of the hugely valuable, dozens of initiatives and activities and interest launched by associations of patients and people with disabilities over the last year.<\/p>\n<p style=\"text-align: justify\">The decision on the winners of this edition was made by a jury consisting of people of the highest scientific and professional prestige. Specifically, the jury was composed of Tom\u00e1s Castillo, President of the Platform of Patient Organizations; Andoni Lorenzo, President of the Spanish Patients Forum; Est\u00edbaliz Gamboa, Head of the Active Patient program in the Basque Country and Coordinator of the Technical Committee of the MSSSI Citizenship Health Network Network; Eva Carrasco; Scientific Director of the Spanish Breast Cancer Research Group (Geicam); Elsa Gonz\u00e1lez, President of FAPE (Federation of Spanish Press Associations); Emilio de Benito, President of ANIS (National Association of Health Informers); Rodrigo Guti\u00e9rrez, General Director of Quality and Humanization of Health Care of the Ministry of Health of Castilla-La Mancha and President of the Spanish Society of Attention to Health Users; Jes\u00fas Aguilar, President of the General Council of Official Associations of Pharmacists; M\u00e1ximo Gonz\u00e1lez-Jurado, President of the General Council of Nursing; Martin Sell\u00e9s, President of Janssen Cilag; Salvador Pons, Managing Director of Menarini; Tom\u00e1s Olleros, President of Farmasierra; And Humberto Arn\u00e9s, Director General of Farmaindustria, who served as the President of the jury.<\/p>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-2996\" src=\"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/12\/2016-12-13-SOMOS-PACIENTESawards-15-300x182.jpg\" alt=\"2016-12-13-somos-pacientesawards-15-300x182\" width=\"300\" height=\"182\" srcset=\"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/12\/2016-12-13-SOMOS-PACIENTESawards-15-300x182.jpg 300w, https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/12\/2016-12-13-SOMOS-PACIENTESawards-15-300x182-50x30.jpg 50w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p style=\"text-align: justify\">In this way, and divided into two categories (Society and Patients), the winners of the awards fall into the following initiatives:<\/p>\n<p style=\"text-align: justify\"><strong>Patients Category<\/strong> &#8211; Better web or application development: Esclerosismultipleenlinea.org, of the Gaem Foundation, a free health and wellness website that offers the opportunity to those affected by Multiple Sclerosis, as well as to their relatives and people linked to the pathology, to expand their knowledge about the disease. \u00a0In addition, the portal promotes research and knowledge of Multiple Sclerosis within general society and offers social care and counselling to patients and families.<\/p>\n<p style=\"text-align: justify\"><strong>Patients Category<\/strong> &#8211; Best initiative or campaigning within the field of social networks: Challenge 111 The King of the Unions, by Inbolo, a social network \u2018competition\u2019 with more than 400 participants, designed for patients with diabetes with the aim of achieving the highest number of glucose controls which a result of 111 mg \/ dl. without putting post-pandemic glycemia at risk.<\/p>\n<p style=\"text-align: justify\"><strong>Patients Category:<\/strong> Best patient service initiative: Palliative, paediatric care in rare diseases, by D&#8217;Genes. The general objective of the project, carried out in collaboration with the Virgen de la Arrixaca University Hospital of Murcia, was to improve the care and quality of life of paediatric patients with rare diseases and their families, suffering from terminal illness or \u00a0having had no response to treatment. In a comprehensive and personalised way, guaranteeing respect for their dignity and the right to their autonomy.<\/p>\n<p style=\"text-align: justify\"><strong>Patients Category<\/strong> &#8211; Best initiative of social awareness or research promotion: Awareness campaign on epilepsy, the Association of Epilepsy by the Valencian Community (ALCE), with the purpose of normalizing epilepsy and building a real public opinion, migrating away from myths and false ideas; to spread knowledge of epilepsy and its problems amongst the population; and to ensure that institutions and the media become positive opinion makers in order to change society&#8217;s view of the disease.<\/p>\n<p style=\"text-align: justify\"><strong>Patients Category<\/strong> &#8211; \u00a0Initiative preferred by users of Somos Pacientes, elected through online voting with the participation of more than 17,900 voters.- AMiMeToca, of the Spanish Association of Leukodystrophies (ELA), a campaign of awareness in social networks that has had the participation of Known faces to publicize an App donations, intended to raise funds, with the simple discharge of which is allocated the amount to the Association.<\/p>\n<p style=\"text-align: justify\"><strong>Society Category<\/strong> &#8211; In love and cancer, by the More Than Ideas Foundation, an information and support book that addresses the real life problems partners of cancer patients face, identifying strategies that minimize the physical, emotional and social consequences that the disease produces within the relationship of the couple, and in each one of its members.<\/p>\n<p style=\"text-align: justify\">The various winners of the \u00a0Patients Category were awarded a commemorative trophy together with a sum of \u20ac 3,000. The award in the Society Category is limited to the trophy. In total, \u2018We Are Patients\u2019 received more than 120 applications to attend the second round of these awards, which have generated considerable expectation amongst the community of patients and people with disabilities in Spain.<\/p>\n<p style=\"text-align: justify\">The delivery of the II round of these awards has put the finishing touch to the celebration of the IV Jornada Somos Patientes. The event was held in the auditorium of the College of Architects of Madrid, with a capacity of more than 200 people, mostly representatives of associations of patients and people with disabilities, as well as professional groups, health administrations and pharmaceutical companies, under the chairmanship of the Secretary General of Health and Consumer Affairs, Javier Castrodeza.<\/p>\n<p style=\"text-align: justify\">\u2018We Are Patients\u2019 (<a href=\"http:\/\/www.somospacientes.com\">www.somospacientes.com<\/a>) is an initiative launched to generate an online community of associations of patients and people with disabilities, which already has more than 1,650 entities, and offers a shared space of information, participation, training , services and collaborative work to all these organizations.<\/p>\n<p style=\"text-align: justify\"><a href=\"https:\/\/www.farmaindustria.es\/web\/fotografias\/entrega-de-los-ii-premios-somos-pacientes\/\">Somos Pacientes Awards 2016 &#8211; Photo gallery<\/a><\/p>\n<p style=\"text-align: justify\"><a href=\"http:\/\/www.somospacientes.com\/streamings\/iv-jornada-somos-pacientes-y-entrega-de-la-ii-edicion-de-los-premios-somos-pacientes\/\">Somos Pacientes Awards 2016 &#8211; Video (in Spanish)\u00a0<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cancer, leukodystrophies, rare pediatric diseases, epilepsy, multiple sclerosis and diabetes. \u00a0The presentation of the II Somos Pacientes Awards on Tuesday December 13th, saw different initiatives being developed and given recognition specifically within the area of the aforementioned six diseases.\u00a0 The Awards recognize the effort, dedication, talent and imagination that patients\u2019 associations have carried out throughout  <a href=\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/\" class=\"read-more\">&hellip;<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-2995","post","type-post","status-publish","format-standard","hentry","tema-pacientes"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The II Somos Pacientes (\u2018We Are Patients\u2019) Awards recognized the best initiatives developed for the benefit of patients - FarmaIndustria<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The II Somos Pacientes (\u2018We Are Patients\u2019) Awards recognized the best initiatives developed for the benefit of patients - FarmaIndustria\" \/>\n<meta property=\"og:description\" content=\"Cancer, leukodystrophies, rare pediatric diseases, epilepsy, multiple sclerosis and diabetes. \u00a0The presentation of the II Somos Pacientes Awards on Tuesday December 13th, saw different initiatives being developed and given recognition specifically within the area of the aforementioned six diseases.\u00a0 The Awards recognize the effort, dedication, talent and imagination that patients\u2019 associations have carried out throughout &hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"FarmaIndustria\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pages\/Farmaindustria\/730634013647836?ref=hl\" \/>\n<meta property=\"article:published_time\" content=\"2016-12-23T11:56:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2016-12-23T11:57:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/12\/2016-12-13-SOMOS-PACIENTESawards-15-300x182.jpg\" \/>\n<meta name=\"author\" content=\"Nathalie Rooney\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@FarmaIndustria\" \/>\n<meta name=\"twitter:site\" content=\"@FarmaIndustria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nathalie Rooney\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/\"},\"author\":{\"name\":\"Nathalie Rooney\",\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/#\/schema\/person\/0d4299f2aea1d36b54db40fc10230603\"},\"headline\":\"The II Somos Pacientes (\u2018We Are Patients\u2019) Awards recognized the best initiatives developed for the benefit of patients\",\"datePublished\":\"2016-12-23T11:56:42+00:00\",\"dateModified\":\"2016-12-23T11:57:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/\"},\"wordCount\":978,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/12\/2016-12-13-SOMOS-PACIENTESawards-15-300x182.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/\",\"url\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/\",\"name\":\"The II Somos Pacientes (\u2018We Are Patients\u2019) Awards recognized the best initiatives developed for the benefit of patients - FarmaIndustria\",\"isPartOf\":{\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/12\/2016-12-13-SOMOS-PACIENTESawards-15-300x182.jpg\",\"datePublished\":\"2016-12-23T11:56:42+00:00\",\"dateModified\":\"2016-12-23T11:57:19+00:00\",\"author\":{\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/#\/schema\/person\/0d4299f2aea1d36b54db40fc10230603\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/#primaryimage\",\"url\":\"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/12\/2016-12-13-SOMOS-PACIENTESawards-15-300x182.jpg\",\"contentUrl\":\"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/12\/2016-12-13-SOMOS-PACIENTESawards-15-300x182.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.farmaindustria.es\/web_en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The II Somos Pacientes (\u2018We Are Patients\u2019) Awards recognized the best initiatives developed for the benefit of patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/#website\",\"url\":\"https:\/\/www.farmaindustria.es\/web_en\/\",\"name\":\"FarmaIndustria\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.farmaindustria.es\/web_en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.farmaindustria.es\/web_en\/#\/schema\/person\/0d4299f2aea1d36b54db40fc10230603\",\"name\":\"Nathalie Rooney\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g\",\"caption\":\"Nathalie Rooney\"},\"url\":\"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/author\/franfranco\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The II Somos Pacientes (\u2018We Are Patients\u2019) Awards recognized the best initiatives developed for the benefit of patients - FarmaIndustria","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/","og_locale":"en_US","og_type":"article","og_title":"The II Somos Pacientes (\u2018We Are Patients\u2019) Awards recognized the best initiatives developed for the benefit of patients - FarmaIndustria","og_description":"Cancer, leukodystrophies, rare pediatric diseases, epilepsy, multiple sclerosis and diabetes. \u00a0The presentation of the II Somos Pacientes Awards on Tuesday December 13th, saw different initiatives being developed and given recognition specifically within the area of the aforementioned six diseases.\u00a0 The Awards recognize the effort, dedication, talent and imagination that patients\u2019 associations have carried out throughout &hellip;","og_url":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/","og_site_name":"FarmaIndustria","article_publisher":"https:\/\/www.facebook.com\/pages\/Farmaindustria\/730634013647836?ref=hl","article_published_time":"2016-12-23T11:56:42+00:00","article_modified_time":"2016-12-23T11:57:19+00:00","og_image":[{"url":"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/12\/2016-12-13-SOMOS-PACIENTESawards-15-300x182.jpg","type":"","width":"","height":""}],"author":"Nathalie Rooney","twitter_card":"summary_large_image","twitter_creator":"@FarmaIndustria","twitter_site":"@FarmaIndustria","twitter_misc":{"Written by":"Nathalie Rooney","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/#article","isPartOf":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/"},"author":{"name":"Nathalie Rooney","@id":"https:\/\/www.farmaindustria.es\/web_en\/#\/schema\/person\/0d4299f2aea1d36b54db40fc10230603"},"headline":"The II Somos Pacientes (\u2018We Are Patients\u2019) Awards recognized the best initiatives developed for the benefit of patients","datePublished":"2016-12-23T11:56:42+00:00","dateModified":"2016-12-23T11:57:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/"},"wordCount":978,"commentCount":0,"image":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/12\/2016-12-13-SOMOS-PACIENTESawards-15-300x182.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/","url":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/","name":"The II Somos Pacientes (\u2018We Are Patients\u2019) Awards recognized the best initiatives developed for the benefit of patients - FarmaIndustria","isPartOf":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/12\/2016-12-13-SOMOS-PACIENTESawards-15-300x182.jpg","datePublished":"2016-12-23T11:56:42+00:00","dateModified":"2016-12-23T11:57:19+00:00","author":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/#\/schema\/person\/0d4299f2aea1d36b54db40fc10230603"},"breadcrumb":{"@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/#primaryimage","url":"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/12\/2016-12-13-SOMOS-PACIENTESawards-15-300x182.jpg","contentUrl":"https:\/\/www.farmaindustria.es\/web_en\/wp-content\/uploads\/sites\/3\/2016\/12\/2016-12-13-SOMOS-PACIENTESawards-15-300x182.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/2016\/12\/23\/ii-somos-pacientes-patients-awards-recognized-best-initiatives-developed-benefit-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.farmaindustria.es\/web_en\/"},{"@type":"ListItem","position":2,"name":"The II Somos Pacientes (\u2018We Are Patients\u2019) Awards recognized the best initiatives developed for the benefit of patients"}]},{"@type":"WebSite","@id":"https:\/\/www.farmaindustria.es\/web_en\/#website","url":"https:\/\/www.farmaindustria.es\/web_en\/","name":"FarmaIndustria","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.farmaindustria.es\/web_en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.farmaindustria.es\/web_en\/#\/schema\/person\/0d4299f2aea1d36b54db40fc10230603","name":"Nathalie Rooney","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a544889d96ab667147c2dddf3cdd9b4cdf2a0044511df45b193d666e09d8b3db?s=96&d=mm&r=g","caption":"Nathalie Rooney"},"url":"https:\/\/www.farmaindustria.es\/web_en\/documents\/press-releases\/author\/franfranco\/"}]}},"_links":{"self":[{"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/posts\/2995","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/comments?post=2995"}],"version-history":[{"count":2,"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/posts\/2995\/revisions"}],"predecessor-version":[{"id":2998,"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/posts\/2995\/revisions\/2998"}],"wp:attachment":[{"href":"https:\/\/www.farmaindustria.es\/web_en\/wp-json\/wp\/v2\/media?parent=2995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}